Profile data is unavailable for this security.
About the company
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
- Revenue in EUR (TTM)2.23bn
- Net income in EUR917.73m
- Incorporated2008
- Employees1.60k
- Locationargenx SELaarderhoogtweg 25AMSTERDAM 1101 EBNetherlandsNLD
- Phone+31 763030
- Websitehttps://www.argenx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Qiagen NV | 1.73bn | 80.79m | 9.01bn | 5.70k | 119.05 | 3.07 | 36.46 | 5.22 | 0.3502 | 0.3502 | 7.87 | 13.57 | 0.3529 | 2.11 | 5.64 | 299,628.60 | 1.65 | 5.76 | 1.91 | 6.88 | 64.09 | 64.31 | 4.68 | 16.85 | 2.83 | -- | 0.2924 | -- | 0.6565 | 5.32 | -75.51 | -- | -9.03 | -- |
Eurofins Scientific SE | 6.95bn | 634.50m | 11.05bn | 62.70k | 18.58 | 2.12 | 8.60 | 1.59 | 3.26 | 1.81 | 35.74 | 28.58 | 0.6384 | 38.44 | 5.00 | 110,868.30 | 6.31 | 7.65 | 7.88 | 9.53 | 22.33 | 23.95 | 9.88 | 11.41 | 1.09 | 7.95 | 0.4014 | 23.54 | 6.70 | 8.78 | 22.85 | 15.36 | 4.45 | -- |
Genmab A/S | 2.79bn | 977.79m | 12.25bn | 2.64k | 12.54 | 2.65 | 11.75 | 4.40 | 113.70 | 113.70 | 323.83 | 538.06 | 0.5434 | 11.54 | 4.38 | 7,754,022.00 | 19.07 | 17.70 | 21.13 | 19.07 | 95.12 | -- | 35.10 | 35.77 | 5.32 | -- | 0.0263 | -- | 30.57 | 31.16 | 80.10 | 28.50 | 21.52 | -- |
argenx SE | 2.23bn | 917.73m | 30.14bn | 1.60k | 35.50 | -- | -- | 13.54 | 13.87 | 13.87 | 34.56 | -- | -- | -- | -- | 1,391,535.00 | -- | -7.11 | -- | -7.96 | 89.73 | -- | 41.24 | -27.22 | -- | -- | -- | -- | 78.60 | 94.61 | 382.34 | -- | 7.88 | -- |
Lonza Group AG | 7.06bn | 682.57m | 42.96bn | 18.69k | 63.90 | 4.32 | 32.26 | 6.09 | 8.92 | 8.92 | 92.21 | 132.06 | 0.3594 | 2.67 | 5.19 | 351,814.20 | 3.48 | 4.79 | 4.23 | 5.84 | 32.86 | 38.15 | 9.69 | 13.32 | 1.04 | 10.25 | 0.3341 | 32.65 | -2.13 | 9.34 | -2.75 | -0.3424 | 12.51 | 7.78 |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 02 Jul 2025 | 2.19m | 3.60% |
Norges Bank Investment Managementas of 15 Apr 2025 | 1.87m | 3.08% |
Wellington Management Co. LLPas of 24 Jun 2024 | 1.82m | 3.00% |
BlackRock Fund Advisorsas of 03 Jul 2025 | 1.22m | 2.01% |
Schroder Investment Management Ltd.as of 31 May 2025 | 1.19m | 1.96% |
BlackRock Advisors (UK) Ltd.as of 04 Jul 2025 | 815.37k | 1.34% |
Geode Capital Management LLCas of 10 Jul 2025 | 643.89k | 1.06% |
Federated Global Investment Management Corp.as of 31 Mar 2025 | 623.14k | 1.03% |
Bellevue Asset Management AGas of 31 Mar 2025 | 576.00k | 0.95% |
Amundi Asset Management SASU (Investment Management)as of 09 Jul 2025 | 452.10k | 0.74% |